<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        133-368-15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2015
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        BROFIX 0.09% eye drops solution
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BROMFENAC SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        0.09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Ophthalmic use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Eye drops, solution
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Dropper Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        58.65
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jamjoom Pharmaceuticals Factory Company" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory Company
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 394]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            JAMJOOM PHARMACEUTICALS CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jamjoom Pharmaceuticals Factory  Company
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        S01BC11
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Brofix&trade; contains bromfenac and belongs to a group of<br />medicines called nonsteroidal anti-inflammatory drugs<br />(NSAIDs). It works by blocking certain substances<br />involved causing inflammation.<br />Therefore, Brofix&trade; is used to reduce eye inflammation<br />following cataract surgery in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not use Brofix&trade;<br />- if you are allergic (hypersensitive) to bromfenac or to<br />any of the other ingredients of Brofix&trade; (see section 6<br />&ldquo;Further information&rdquo;.<br />- if you have experienced asthma, skin allergy or<br />intense inflammation in your nose when using other<br />NSAIDs. Examples of NSAIDs are: acetylsalicylic<br />acid, ibuprofen, ketoprofen,diclofenac.<br />Take special care with Brofix&trade;<br />- if you are using topical steroids (e.g. cortisone), as this<br />may cause unwanted side effects.<br />- if you have bleeding problems (e.g. haemophilia) or<br />have had them in the past, or you are taking other<br />medicines which may prolong bleeding time.<br />- if you have eye problems (e.g. dry eye syndrome,<br />corneal problems).<br />- if you have diabetes.<br />- if you have rheumatoid arthritis.<br />- if you had repeated eye surgery within a short period<br />of time.<br />Children and adolescents<br />Brofix&trade; should not be used in children and<br />adolescents.<br />Taking other medicines<br />Please tell your doctor or pharmacist if you are taking<br />or have recently taken any other medicines, including<br />medicines obtained without prescription.<br />Pregnancy and breastfeeding<br />If you are pregnant or breastfeeding, talk to your doctor<br />before you use Brofix&trade;.<br />Brofix&trade; should not be used during the last three<br />months of pregnancy.<br />Driving and using machines<br />Your vision may be blurred for a short time after using<br />Brofix&trade;. If you experience blurred vision upon using<br />Brofix&trade;, do not drive or use machines until your vision<br />is clear.<br />Important information about some of the<br />ingredients of Brofix&trade;<br />Brofix&trade; contains sodium sulfite which may cause<br />allergic reactions.<br />Brofix&trade; contains benzalkonium chloride,<br />a preservative which may cause eye irritation.<br />Do not use Brofix&trade; while wearing contact lenses, since<br />benzalkonium chloride is known to discolour them.<br />Additionally, wearing contact lenses is not<br />recommended after cataract surgery.<br />Therefore, do not wear contact lenses whilst using<br />Brofix&trade;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use Brofix&trade; exactly as your doctor has told<br />you. You should check with your doctor or pharmacist<br />if you are not sure.<br />Dose and duration of treatment<br />For the treatment of postoperative inflammation in<br />patients who have undergone cataract extraction, one<br />drop of Brofix&trade; should be applied to the affected<br />eye(s) once daily beginning 1 day prior to cataract<br />surgery, continued on the day of surgery, and through<br />the first 14 days of the postoperative period.<br />Administration<br />- Unscrew the cap from the bottle, check the dropper is<br />clean.<br />- Pull your lower eyelid gently down, and then carefully<br />instill one drop inside the lower eyelid, in the corner<br />closest to the nose.<br />- Release the lower eyelid, and blink a few times to<br />make sure the eye is covered by the liquid.<br />- Repeat the procedure for your other eye, if it also<br />needs treatment.<br />- When you have finished, replace the protective cap<br />tightly to prevent spilling or spoilage.<br />If you use any other eye drops, wait at least five<br />minutes between using Brofix&trade; and the other drops.<br />If you use more Brofix&trade; than you should<br />Rinse out your eye with warm water. Do not put in any<br />more drops until it is time for your next regular dose. If<br />Brofix&trade; is accidentally ingested, fluids (e.g. a glass of<br />water) should be taken to dilute the medicine.</p><p>If you forget to use Brofix&trade;<br />Use a single dose as soon as you remember. If it is almost<br />time for the next dose, leave out the missed dose.<br />Continue with the next regularly scheduled dose. Do not<br />use a double dose to make up for a forgotten dose.<br />If you stop using Brofix&trade;<br />Do not stop using Brofix&trade; without speaking to your<br />doctor.<br />If you have any further questions on the use of this<br />medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Brofix&trade; can cause side effects,<br />although not everybody gets them.<br />If you experience decreased or blurred vision the week<br />after the end of treatment, you should contact your doctor<br />immediately.<br />If you notice any of the following side effects while<br />using the drops, contact your doctor immediately:<br />Uncommon side effects (Affects 1 to 10 users in 1,000)<br />Foreign body sensation in the eye, redness and<br />inflammation of the eye, damage and inflammation of the<br />surface of the eye, eye discharge, itching, irritation or<br />pain of the eye, swelling or bleeding of the eyelid,<br />impaired vision due to inflammation, floaters or moving<br />spots before the eyes or diminishing vision that can<br />indicate bleeding or damage of the back of the eye<br />(retina), ocular discomfort, sensitivity to light, reduced or<br />blurred vision, swelling of the face, cough, nosebleeding<br />or runny nose.<br />Rare side effects (Affects 1 to 10 users in 10,000)<br />Damage of the eye surface, redness of the eye, asthma.<br />If any of the side effects gets serious or if you notice any<br />side effects not listed in this leaflet, please tell your<br />doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.<br />- Do not store above 30 &ordm;C.<br />- Do not use Brofix&trade; after the expiry date which is<br />stated on the bottle and outer carton after &ldquo;EXP&rdquo;.<br />- Discard after 30 days of opening.<br />- Medicines should not be disposed of via wastewater or<br />household waste. Ask your pharmacist how to dispose of<br />medicines no longer required. These measures will help<br />to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What Brofix&trade; contains<br />Each ml contains:<br />Active Ingredients: 1.035mg bromfenac sodium<br />sesquihydrate equivalent to 0.9 mg bromfenac free acid.<br />Other ingredients are benzalkonium chloride, boric acid,<br />sodium tetraborate (Borax), disodium edetate,<br />polysorbate 80, sodium sulfite anhydrous, povidone<br />K29/32, sodium hydoxide IN (to adjust pH) and water for<br />Injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Brofix™ Eye Drops is a clear yellow solution.
Brofix™ Eye Drops, 5 ml filled in LDPE opaque bottles.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Marketing Authorisation Holder and<br />Manufacturer<br />Jamjoom Pharmaceuticals Factory Co.,<br />Jeddah, Makkah Region, Saudi Arabia.<br />Tel: +966-12-6081111 Fax: +966-12-6081222<br />Website: www.jamjoompharma.com<br />Please report adverse drug events to:<br />&bull; Saudi Arabia:<br />The National Pharmacovigilance Centre (NPC):<br />o Fax: +966-11-205-7662<br />o SFDA Call Center: 19999<br />o E-mail: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States:<br />&minus; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                22-04-2024
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>تحتوي بروفكس على البرومفيناك وتنتمي إلى مجموعة من&nbsp;<br />(NSAIDs) الأدوية تسمى مضادات الالتهاب غير الستيرويدية<br />ويعمل عن طريق تثبيط بعض المواد التي تسبب الالتهاب. لهذا<br />تستخدم بروفكس للتخفيف من التهاب العين الذي يتبع عمليات<br />إعتام عدسة العين الجراحية &quot;الكتاراكت&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&nbsp;لا تستخدم بروفكس:<br />- إذا كنت تعاني من فرط حساسية للبرومفيناك أو لأي من مكونات<br />بروفكس الأخرى (أنظر قسم ٦ &quot;معلومات إضافية&quot; ).<br />- إذا كنت تواجه نوبات ربو، حساسية في الجلد أو التهاب شديد في<br />الأنف عند استخدام مضادات الالتهاب غير الستيرويدية الأخرى.<br />مثال على ذلك: حمض أسيتيل الساليسيليك، ايبوبروفين،<br />كيتوبروفين، ديكلوفيناك.<br />:&trade; إتخذ إحتياطات خاصة عند استخدام بروفكس<br />- إذا كنت تستخدم الستيرويدات الموضعية (مثل الكورتيزون) ،<br />لأنها قد تتسبب في حدوث آثار جانبية غير مرغوب فيها.<br />- إذا كنت تعاني حالياً أو فيما سبق من مشاكل في النزيف (مثل<br />مرض الهيموفيليا &quot;الناعور&quot;) ، أو كنت تتناول أدوية أخرى قد<br />تطيل من فترة النزف.<br />- إذا كان لديك مشاكل في العين (مثل متلازمة العين الجافة أو<br />مشاكل في القرنية).<br />- إذا كان لديك مرض السكري.<br />- إذا كنت تعاني من التهاب المفاصل الروماتويدي.<br />- إذا كنت قد أجريت عمليات جراحية متكررة في العين خلال فترة<br />قصيرة من الوقت.<br />الأطفال و المراهقين:<br />مع الأطفال أو المراهقين. &trade; لا ينبغي استخدام بروفكس<br />تناول أدوية اخرى:<br />يرجى إخبار طبيبك أو الصيدلي إذا كنت تتناول أو تناولت مؤخراً<br />أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها بدون<br />وصفة طبية.<br />الحمل و الرضاعة الطبيعية:<br />إذا كنت حاملاً أو &trade; تحدثي إلى طبيبك قبل استخدام بروفكس<br />تقومين بالرضاعة الطبيعية.<br />أثناء الأشهر الثلاثة الأخيرة من &trade; لا ينبغي استخدام بروفكس<br />الحمل.<br />القيادة واستخدام الآلات:<br />قد يحدث عدم وضوح في الرؤية لفترة قصيرة بعد استخدام<br />إذا واجهت عدم وضوح في الرؤية عند استخدام .&trade; بروفكس<br />فلا تقوم بالقيادة أو استخدام الآلات حتى تتضح ،&trade; بروفكس<br />الرؤية مجدداً.<br />:&trade; معلومات هامة عن بعض مكونات بروفكس<br />على كبريتيت الصوديوم والذي يمكن أن &trade; - تحتوي بروفكس<br />تسبب تفاعلات تحسسية.<br />على كلوريد البنزالكونيوم كمادة حافظة، &trade; - تحتوي بروفكس<br />والذي يمكن أن يتسبب في حدوث تهيج بالعين. لا تقم باستخدام<br />أثناء ارتداء العدسات اللاصقة حيث أنه من المعروف &trade; بروفكس<br />عنه أن يتسبب في تغير لونها، بالإضافة إلى ذلك فإنه من غير<br />المستحب ارتداء العدسات اللاصقة بعد إجراء عمليات إعتام عدسة<br />العين الجراحية &quot;الكتاراكت&quot;. ولهذا فلا تقم باستخدام العدساتاللاصقة أثناء استخدام بروفكس</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>استخدم دائما بروفكس تماما كما وصفها لك طبيبك. يجب عليك&nbsp;<br />أن تتحقق من طبيبك أو الصيدلي إذا كنت غير متأكداً.<br />الجرعة ومدة العلاج:<br />لعلاج التهاب بعد عملية إعتام عدسة العين الجراحية &quot;الكتاراكت&quot;<br />في العين (العينين) &trade; ينبغي وضع قطرة واحدة من بروفكس<br />المصابة مرة واحدة يومياً بداية من يوم واحد قبل جراحة<br />الكتاراكت، وتستمر في يوم الجراحة، و خلال أول ۱٤ يوماً في<br />فترة ما بعد الجراحة.<br />طريقة الاستخدام:<br />- قم بلف الغطاء من الزجاجة، وتحقق من أن القطارة نظيفة.<br />- إسحب الجفن السفلي إلى أسفل برفق، ومن ثم ضع بعناية قطرة<br />واحدة داخل الجفن السفلي، في الزاوية الأقرب إلى الأنف.<br />- حرر الجفن السفلي، أغلق وافتح العين عدة مرات للتأكد من<br />تغطية العين عن طريق السائل.<br />في كلتا العينين كرر نفس الخطوات &trade; - إذا كنت تستخدم بروفكس<br />للعين الأخرى.إذا كانت هي أيضاً تحتاج للعلاج.<br />- قم بإعادة غطاء الزجاجة الى مكانه مباشرة بعد الإستخدام وقم<br />بإحكام الغلق.<br />- إذا كنت تستخدم أي قطرات أخرى للعين، فانتظر خمس دقائق<br />وقطرات العين الأخرى. &trade; على الأقل ما بين استخدام بروفكس<br />أكثر من اللازم: &trade; إذا استخدمت كمية من بروفكس<br />قم بشطف عينيك بالماء الدافئ. لا تضع أي كمية إضافية من قطرة<br />حتى يحين وقت جرعتك التالية المعتادة. إذا تم بلع &trade; بروفكس<br />بطريق الخطأ، ينبغي أن يتم شرب سوائل (مثل كوب &trade; بروفكس<br />من الماء) لتخفيف تركيز الدواء.<br />:&trade; إذا نسيت استخدام بروفكس<br />إستخدم جرعة واحدة بمجرد تذكرك، إذا كان قد حان وقت الجرعة<br />التالية، إترك الجرعة التي نسيتها واستمر على جدول جرعاتك<br />المعتاد. لا تقم بمضاعفة الجرعة لتعويض ما فاتك من جرعات.<br />:&trade; إذا توقفت عن استخدام بروفكس<br />دون ان تتحدث الى الطبيب. &trade; لا تتوقف عن استخدام بروفكس<br />إذا كان لديك أي أسئلة إضافية حول استخدام هذا الدواء، فاسأل<br />طبيبك أو الصيدلي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل باقي الأدوية يمكن أن تتسبب بروفكس في حدوث آثار<br />جانبية بالرغم من عدم تعرض جميع الأشخاص لها.<br />- إذا واجهت ضعف أو عدم وضوح في الرؤية أثناء الأسبوع الذي<br />يلي الإنتهاء من العلاج، يجب عليك الاتصال بالطبيب على الفور.<br />إذا لاحظت ظهور أي من الآثار الجانبية التالية أثناء استخدام<br />قم بالاتصال بطبيبك فوراً: ،&trade; بروفكس<br />آثار جانبية غير شائعة (تؤثر على ما بين ۱ إلى ۱۰ لكل<br />۱,۰۰۰ شخص)<br />الإحساس بجسم غريب واحمرار والتهاب في العين، تلف والتهاب<br />في سطح العين، إفرازات من العين، حكة، تهيج أو ألم في العين،<br />تورم أو نزيف من جفن العين، إضطراب في الابصار بسبب<br />الالتهابات، الذُّبابُ الطَّائِر (العَوَائم) أو رؤية نقاط متحركة أمام<br />العين أو تناقص في الرؤية والذي يمكن أن يكون مؤشراً إلى<br />نزيف أو تلف في الجزء الخلفي من العين (الشبكية)، عدم الراحة<br />في العين، حساسية تجاه الضوء، ضعف أو عدم وضوح في<br />الرؤية، تورم في الوجه، سعال، ونزيف من الأنف أو رشح.<br />آثار جانبية نادرة (تؤثر على ما بين ۱ إلى ۱۰ لكل ۱۰,۰۰۰<br />شخص)<br />تلف في سطح العين، واحمرار في العين، نوبات ربو. إذا كان أي<br />من الآثار الجانبية الخطيرة يحصل أو إذا لاحظت أي آثار جانبية<br />غير المذكورة في هذه النشرة، يرجى إخبار الطبيب أو الصيدلي.<br />إذا تحول أي من الآثار الجانبية الى مرحلة أكثر خطورة أو إذا<br />لاحظت حدوث أية آثار جانبية أخرى غير مدرجة في هذه النشرة<br />يرجى إخبار طبيبك أو الصيدلي بها.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يُحفظ بعيداً عن متناول و مرأى الأطفال.<br />- يُحفظ في درجة حرارة لا تزيد عن ۳۰ &deg;م.<br />بعد انتهاء تاريخ الصلاحية &trade; - لا تستخدم قطرة بروفكس<br />والمدون على الزجاجة وعلى العبوة الكرتونية الخارجية بعد كلمة .&ldquo;EXP&rdquo;<br />- يتلف الدواء بعد ۳۰ يوماً من فتح الغطاء.<br />- لا ينبغي التخلص من الأدوية عن طريق مياه الصرف أو<br />النفايات المنزلية. إسأل الصيدلي عن طريقة التخلص من الأدوية<br />الغير مرغوب فيها فسوف تساعد هذه الإجراءات على حماية<br />البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>كل ۱ مل يحتوي على:<br />المادة الفعالة: 1.035&nbsp;ملجم برومفيناك صوديوم سيسكويهيدرات &cedil;&nbsp;<br />(يكافيء0.9&nbsp;&nbsp;ملجم من حمض البرومفيناك الخالص). &cedil;<br />المكونات الأخرى: كلوريد البنزالكونيوم، حامض البوريك،<br />صوديوم ثلاثى البورات (بوراكس)، الصوديوم إيديتات،<br />بوليسوربيت ۸۰ ، كبريتيت الصوديوم اللامائية، بوفيدون<br />هيدروكسيد الصوديوم و ماء للحقن. ،K29/32</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p style="text-align:right">بروفكس قطرة للعين محلول أصفر نقى.<br />بروفكس قطرة للعين ٥ مل في قطارة من البولي إيثيلين منخفض الكثافة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>اسم وعنوان مالك رخصة التسویق و المصنع:<br />شركة مصنع جمجوم للأدویة ،<br />جدة، منطقة مكة، المملكة العربیة السعودیة.<br />+۹٦٦-۱۲- الھاتف: ٦۰۸۱۱۱۱<br />+۹٦٦-۱۲- فاكس: ٦۰۸۱۲۲۲<br />www.jamjoompharma.com : الموقع الإلكتروني<br />للإبلاغ عن أي أثار جانبیھ:<br />&bull; المملكة العربیة السعودیة:<br />:(NPC) المركز الوطني للتیقظ الدوائي<br />+۹٦٦-۱۱-۲۰٥- فاكس: ۷٦٦۲ o<br />مركز اتصال الھیئة العامة للغذاء والدواء: ۱۹۹۹۹ o<br />npc.drug@sfda.gov.sa : برید إلكتروني o<br />https://ade.sfda.gov.sa : الموقع الالكتروني o<br />&bull; دول الخلیج الأخرى:<br />- الرجاء الاتصال بالمؤسسات و الھیئات الوطنیة في كل دولة.</p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            22-04-2024
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Brofix 0.9 mg/ml eye drops, solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One ml of solution contains 0.9 mg bromfenac (as sodium sesquihydrate).
One drop contains approximately 33 micrograms bromfenac.
Excipient:
Each ml of solution contains 50 micrograms of benzalkonium chloride.
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Eye drops, solution.
Yellow, clear solution, free from visible particles.
pH: 8.0-8.6; osmolality: 265-330 mOsmol/kg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of postoperative ocular inflammation following cataract extraction in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Use in adults, including the elderly<br />For the treatment of postoperative inflammation in patients who have undergone cataract extraction, one<br />drop of Bromfenac&trade; should be applied to the affected eye(s) once daily beginning 1 day prior to cataract<br />surgery, continued on the day of surgery, and through the first 14 days of the postoperative period.<br />Paediatric population<br />The safety and efficacy of bromfenac in paediatric patients has not been established. No data are available.<br />Hepatic and renal impairment<br />Bromfenac has not been studied in patients with hepatic disease or renal impairment.<br />Method of administration<br />For ocular use.<br />If more than one topical ophtalmic medicinal product is being used, each one should be administered at<br />least 5 minutes apart.<br />To prevent contamination of the dropper-tip and solution, care must be taken not to touch the eyelids,<br />surrounding areas or other surfaces with the dropper-tip of the bottle. Instruct patient to keep the bottle<br />tightly closed when not in use. Contact lenses should not be worn during treatment with Bromfenac<br />(see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bromfenac must not be used in patients with known hypersensitivity to bromfenac, to any of the
excipients, or to other non-steroidal anti-inflammatory medicinal products (NSAIDs).
Bromfenac is contraindicated in patients in whom attacks of asthma, urticaria or acute rhinitis are
precipitated by acetylsalicylic acid or by other medicinal products with prostaglandin synthetase inhibiting
activity.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>All topical NSAIDs may slow or delay healing like topical corticosteroids. Concomitant use of NSAIDs<br />and topical steroids may increase the potential for healing problems.<br />Bromfenac contains sodium sulphite which may cause allergic-type reactions including anaphylactic<br />symptoms and life-threatening or less severe asthmatic episodes in susceptible patients.<br />Cross-sensitivity<br />There is the potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives, and other<br />NSAIDs. Therefore, caution should be used when treating individuals who have previously exhibited<br />sensitivities to these medicinal products and potential risks and benefit should be carefully evaluated.<br />Susceptible persons<br />In susceptible patients, continued use of topical NSAIDs, including Bromfenac may result in epithelial<br />breakdown, corneal thinning, corneal erosion, corneal ulceration or corneal perforation. These events may<br />be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately<br />discontinue use of topical NSAIDs and should be closely monitored for corneal health. Consequently in at<br />risk patients concomitant use of ophthalmic corticosteroids with NSAIDs may lead to a higher risk of<br />corneal adverse events.<br />Postmarketing experience<br />Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries,<br />corneal denervation, corneal epithelial defects, diabetes mellitus and ocular surface diseases e.g. dry eye<br />syndrome, rheumatoid arthritis or repeat ocular surgeries within a short period of time may be at increased<br />risk for corneal adverse reactions which may become sight threatening. Topical NSAIDs should be used<br />with caution in these patients.<br />There have been reports that ophthalmic NSAIDs may cause increased bleeding of ocular tissues<br />(including hyphaema) in conjunction with ocular surgery. Bromfenac should be used with caution in<br />patients with known bleeding tendencies or who are receiving other medicinal products which may prolong<br />bleeding time.<br />Ocular infection<br />An acute ocular infection may be masked by the topical use of anti-inflammatory medicinal products.<br />Use of contact lenses<br />In general, contact lens wear is not recommended during the postoperative period following cataract<br />surgery. Therefore, patients should be advised not to wear contact lenses during treatment with Bromfenac.<br />Excipients<br />Since Bromfenac contains benzalkonium chloride, close monitoring is required with frequent or prolonged<br />use.<br />Benzalkonium chloride is known to discolour soft contact lenses. Contact with soft contact lenses must be<br />avoided.<br />Benzalkonium chloride has been reported to cause eye irritation, punctuate keratopathy and/or toxic<br />ulcerative keratopathy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Formal interaction studies have not been performed, but no interactions with antibiotic eye drops used in<br />conjunction with surgery have been reported.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Category C.</p><p>There are no adequate data from the use of bromfenac in pregnant women. Studies in animals have shown<br />reproductive toxicity (see section 5.3). The potential risk for humans is unknown. Since the systemic<br />exposure in non-pregnant women is negligible after treatment with Bromfenac, the risk during pregnancy<br />could be considered low.<br />However, because of the known effects of prostaglandin biosynthesis-inhibiting medicinal products on the<br />foetal cardiovascular system (closure of ductus arteriosus), the use of Bromfenac during third trimester<br />pregnancy should be avoided. The use of Bromfenac is in general not recommended during pregnancy<br />unless the benefit outweighs the potential risk.<br />Breast-feeding<br />It is unknown whether bromfenac or its metabolites are excreted in human milk. Animal studies have<br />shown excretion of bromfenac in the milk of rats following very high oral doses (see section 5.3). No<br />effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breastfeeding<br />woman to bromfenac is negligible. Bromfenac can be used during breast-feeding.<br />Fertility<br />No effects of bromfenac on the fertility were observed in animal studies. In addition the systemic exposure<br />to bromfenac is negligible; for this reason no pregnancy testing or contraceptive measures are required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Transient blurring of vision may occur on instillation. If blurred vision occurs at instillation refrain from<br />driving or using machines until vision is clear.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Summary of the safety profile<br />Based on an analysis of all patients receiving Bromfenac in a clinical trial for treatment of post-operative<br />inflammation following cataract surgery (n = 973, whereof n=356 in studies performed in the U.S and<br />n=617 in studies performed in Japan), a total of 3.4% of patients (6.7% in U.S. studies and 1.3% in<br />Japanese studies) experienced one or more adverse reactions. The most common or most important<br />reactions in the pooled studies were abnormal sensation in eye (0.5%), corneal erosion (mild or moderate)<br />(0.4%), eye pruritus (0.4%), eye pain (0.3%) and eye redness (0.3%). Corneal adverse reactions were only<br />observed in the Japanese population. Adverse reactions rarely led to withdrawal, with a total of 8 (0.8%)<br />patients who prematurely discontinued treatment in a study due to an adverse reaction. These comprised 3<br />(0.3%) patients with mild corneal erosion, 2 (0.2%) patients with eyelid oedema and 1 (0.1%) patient each<br />with abnormal sensation in eye, corneal oedema, or eye pruritus.<br />Tabulated list of adverse reactions<br />The following adverse reactions were classified according to the following convention: very common<br />(&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000), or<br />very rare (&lt;1/10,000). Within each frequency grouping, adverse reactions are presented in order of<br />decreasing seriousness.</p><p><img alt="" src="data:image/png;base64,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" /></p><p>&bull; Reporting of suspected adverse reactions<br />&bull; To reports any side effect(s):<br />&bull; Saudi Arabia:<br />&bull; The National Pharmacovigilance and Drug Safety Centre (NPC)<br />&bull; Fax: +966-11-205-7662<br />&bull; Call NPC at 19999<br />&bull; E-mail: npc.drug@sfda.gov.sa<br />&bull; Website: https://ade.sfda.gov.sa<br />&bull; Other GCC States:<br />- Please contact the relevant competent authority.</p><p>Patients with evidence of corneal epithelial breakdown should immediately discontinue use of Bromfenac<br />and should be monitored closely for corneal health (see section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>If Bromfenac is accidentally ingested, fluids should be taken to dilute the medicinal product.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Ophtalmologics, Antiinflammatory agents, non-steroids, ATC code: S01BC11<br />Mechanism of action<br />Bromfenac is a non-steroidal anti-inflammatory drug (NSAID) that has anti-inflammatory activity which is<br />thought to be due to its ability to block prostaglandin synthesis by inhibiting primarily cyclooxygenase 2<br />(COX-2). Cyclooxygenase 1 (COX-1) is only inhibited to a small extent.<br />In vitro, bromfenac inhibited the synthesis of prostaglandins in the rabbit iris ciliary body. The IC50-values<br />were lower for Bromfenac (1.1 &mu;M) than for indometacin (4.2 &mu;M) and pranoprofen (11.9 &mu;M)<br />Bromfenac at concentrations of 0.02%, 0.05%, 0.1% and 0.2% inhibited almost all signs of ocular<br />inflammation in an experimental uveitis model in rabbits.<br />Clinical efficacy<br />Two Phase II multicentre, randomised, double-masked, parallel group studies were conducted in Japan, and<br />two Phase III multicentre, randomised (2:1), double-masked, parallel group, placebo-controlled studies<br />were conducted in the US to assess the clinical safety and efficacy of Bromfenac dosed twice daily in the<br />treatment of post-operative inflammation in patients undergoing cataract surgery. In these studies, study<br />substance was administered approximately 24 hours after cataract surgery and continued for up to 14 days.<br />Treatment effect was evaluated up to 29 days.<br />A significantly greater proportion of patients in the Bromfenac group 64.0% vs. 43.3% in the placebo<br />group (p&lt;0.0001) experienced complete clearance of ocular inflammation at study day 15. There was<br />significantly less anterior chamber cells and flare within the first 2 weeks post-surgery (85.1% of patients<br />with flare score of &le;1) vs. placebo (52%). The difference in the rate of inflammation clearance showed as<br />early as day 3.<br />In a large, well controlled study that was conducted in Japan, Bromfenac was shown to be as effective as<br />pranoprofen ophthalmic solution.<br />Paediatric population<br />The European Medicines Agency has waived the obligation to submit the results of studies with Bromfenac<br />in all subsets of the paediatric population in postoperative ocular inflammation (see section 4.2 for<br />information on paediatric use)</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Bromfenac efficiently permeates the cornea of cataract patients: A single dose resulted in a mean peak<br />aqueous humour concentrations of 79&plusmn;68 ng/ml at 150-180 minutes after dosing. Concentrations were<br />maintained for 12 hours in aqueous humour with measurable levels up to 24 hours in major ocular tissues<br />including the retina. Following twice daily dosing with bromfenac eye drops plasma concentrations were<br />not quantifiable.<br />Distribution<br />Bromfenac shows high binding to plasma proteins. In vitro, the 99.8% were bound to proteins in human<br />plasma.<br />No biological relevant melanin binding was observed in vitro.<br />Studies in rabbits using radio-labelled bromfenac have demonstrated that highest concentrations after<br />topical administration are observed in the cornea followed by the conjunctiva and the aqueous humour.<br />Only low concentrations were observed in the lens and vitreous.<br />Biotransformation<br />In vitro studies indicate that bromfenac is mainly metabolised by CYP2C9, which is absent in both irisciliary<br />body and retina/choroid and the level of this enzyme in the cornea is less than 1% compared to the<br />corresponding hepatic level.<br />In orally treated humans unchanged parent compound is the major component in plasma. Several<br />conjugated and unconjugated metabolites have been identified with the cyclic amide being the major<br />urinary metabolite.<br />Excretion<br />After ocular administration the half-life of bromfenac in aqueous humour is 1.4 h indicating rapid<br />elimination.<br />After oral administration of 14C-bromfenac to healthy volunteers, urinary excretion was found to be the<br />major route of radioactive excretions, accounting for approximately 82% while faecal excretion<br />represented approximately 13% of the dose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety,<br />pharmacology, &#39;repeated-dose&#39; toxicity, genotoxicity and carcinogenic potential. However, 0.9 mg/kg/day<br />in rats at oral doses (900 times the recommended ophthalmic dose) caused embryo-foetal lethality,<br />increased neonatal mortality, and reduced postnatal growth. Pregnant rabbits treated orally with 7.5<br />mg/kg/day (7500 times the recommended ophthalmic dose) caused increased post-implantation loss (see<br />section 4.6).<br />Animal studies have shown excretion of bromfenac in breast milk when applied orally at doses of 2.35<br />mg/kg which is 2350 times the recommended ophthalmic dose. However, following ocular administration<br />plasma levels were not detectable (see section 5.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Benzalkonium Chloride<br />Boric acid<br />Sodium tetraborate<br />Disodium Edetate<br />Polysorbate 80<br />Sodium Sulfite Anhydrous<br />Povidone K29 32<br />Sodium Hyroxide 1N<br />Water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Unopened: 24 months
Discard after 30 days of opening.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>5 ml ophthalmic solution, packed in 10 ml LDPE opaque bottle</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.<br />Any unused medicinal product or waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jamjoom Pharmaceuticals Factory Company
PO Box 6267
Jeddah
Kingdom of Saudi Arabia
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2024
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>